Overview
- The Defense Health Agency posted clinical guidance on Sept. 2 that would have required testosterone blood tests for male service members 30 and older, and the Pentagon removed that guidance on Sept. 3 saying the draft was temporarily rescinded to allow updates.
- Under the posted guidance men 30 and older faced routine blood testing triggered by a screening questionnaire while younger men could be tested on request or for clinical signs, and women would receive narrower questionnaire-based screening with limited off-label testosterone use.
- The Pentagon said the interim guidance remains in force and that a final clinical guidance will be issued shortly, so Hegseth’s underlying screening mandate is still active even though the detailed rules were withdrawn.
- Endocrinologists and other clinicians warned that population-level testosterone screening can lead to false diagnoses or unnecessary treatment because levels fluctuate and single tests are unreliable, and they cited risks from inappropriate testosterone therapy such as clotting, fertility harms, and cardiovascular effects.
- The move has political and legal implications because the policy is a high-profile priority of Defense Secretary Pete Hegseth, it highlights a contrast with limits on transgender hormone care, and the FDA will hold an expert meeting on testosterone use in mid-September that could affect how the program is shaped.